Scientific publications

Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29(5 Suppl. 14): 3-9

Asano H, Toyooka S, Tokumo M, et al: Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006; 12: 43-48

Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23 (31): 8081-8092

Board RE, Thelwell NJ, Ravetto PF, et al. Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 2008; 54 (4): 757-760

Carpenter G. The biochemistry and physiology of the receptor-kinase for epidermal growth factor. Mol Cell Endocrinol 1983; 31 (1): 1-19

Chinkers M, Cohen S. Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein. Nature 1981; 290: 516-519

Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res 2001; 7: 2958-2970

Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962; 237: 1555-1562

Cohen S, Carpenter G, King L Jr. Epidermal growth factor receptor-kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 1980; 255: 4834-4842

Doroshow JH. Targeting EGFR in non-small cell lung cancer. N Engl J Med 2005; 353 (2): 200-202

Eberhard DA, Giaccone G, Johnson BE. Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26 (6): 983-993

European Medicines Agency (Committee for Medicinal Products for Human Use). Summary of positive opinion for Iressa (gefitinib). London 2009; EMEA/CHMP/200756/2009

Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer. J Clinl Oncol 2003; 21 (12): 2237-2246

Hirsch FR, Bunn PA. EGFR testing in lung cancer is ready for prime time. Lancet Oncology 2009; 10 (5): 432-433

Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24 (31): 5034-5042

Holland PM, Abramson RD, Watson R, et al. Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A. 1991; 88 (16): 7276-7280

Jänne PA, Borras AM, Kuang Y, et al: A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006; 12: 751-758

Kawamoto TK, Sato JD, Le A, et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A. 1983; 80: 1337-1341

Kim D, Lee S, Lee J, et al. Multicenter Phase II study to evaluate efficacy and safety of gefitinib as the first-line treatment for Korean patients (pts) with advanced pulmonary adenocarcinoma harbouring EGFR mutations. J Clin Oncol 2009; 27: (Suppl 15s; abstr 8066)

Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818

Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006; 97: 642-648

Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small cell lung cancer. Clin Cancer Res 2006; 13: 3915-3921

Kobayashi K, Inoue A, Maemondo M, et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a Phase II study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 2009; 27: (Suppl 15s; abstr 8016)

Kresge N, Simoni RD, Hill RL. Precocious newborn mice and epidermal growth factor: the work of Stanley Cohen. J Biol Chem 2006; 281 (10): e10-e11

Kris MG, Natale RB, Herbst RS et al Efficacy of gefitinib (ZD1839, Iressa™), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003; 22: 2149–2158

Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139

Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44: 1002-1007

Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents. J Steroid Biochem Mol Biol 1990; 37 (6): 889-892

Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009

Molina-Vila MA, Bertran-Alamillo J, Reguart N et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 2008; 3 (11): 1224-1235

Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 7276-7282

Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989; 17: 2503-2516

Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl.4): S9-15

Nomoto K, Tsuta K, Takano T, et al: Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006; 126: 608-615

Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005; 7 (3): 413-421

Oda K, Matsuoka Y, Funahashi A, et al. A comprehensive pathway map of epidermal growth factor receptor signalling. Mol Syst Biol 2005; 1: 1-17

Oshita F, Matsukuma S, Yoshihara M, et al. Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Br J Cancer 2006; 95 (8): 1070-1075

Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500

Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumours to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-13311

Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2 (3): e73

Sequist LV, Martins RG, Spigel D, et al. First line gefitinib in patients with advanced non-small-cell lung cancer harbouring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-2449

Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer 2007; 7: 169-181

Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118 (2): 257-262

Sobol RE., Astarita RW., Hofeditz C., et al. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 1987; 79: 403-407

Soderquist AM, Carpenter G. Developments in the mechanism of growth factor action: activation of protein kinase by epidermal growth factor. Fed Proc 1983; 42 (9): 2615-2620

Taron M, Ichinose Y, Rosell R, et al. Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas. Clinical Cancer Research 2005; 11: 5878-5885

Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418-425

Ward WH, Cook PN, Slater AM, et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994; 48 (4): 659-666

Whitcombe D, Theaker J, Guy SP, et al. Detection of PCR products using self-probing amplicons and fluorescence. Nat. Biotechnol 1999; 17: 804-807

Woodburn J. R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther 1999; 82: 241-250

Yarish P, Gazit A, Gilon C, et al. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242 (4880): 933-35

Gefitinib Product Information

Next: EGFR links